These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35411052)

  • 101. Artificial Intelligent Olfactory System for the Diagnosis of Parkinson's Disease.
    Fu W; Xu L; Yu Q; Fang J; Zhao G; Li Y; Pan C; Dong H; Wang D; Ren H; Guo Y; Liu Q; Liu J; Chen X
    ACS Omega; 2022 Feb; 7(5):4001-4010. PubMed ID: 35155895
    [No Abstract]   [Full Text] [Related]  

  • 102. The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease.
    Yang D; Zhao D; Ali Shah SZ; Wu W; Lai M; Zhang X; Li J; Guan Z; Zhao H; Li W; Gao H; Zhou X; Yang L
    Front Neurol; 2019; 10():1155. PubMed ID: 31781020
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson's disease.
    Pereira PAB; Trivedi DK; Silverman J; Duru IC; Paulin L; Auvinen P; Scheperjans F
    NPJ Parkinsons Dis; 2022 Apr; 8(1):39. PubMed ID: 35411052
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Multi-Omics Integration in Mice With Parkinson's Disease and the Intervention Effect of Cyanidin-3-
    Wang W; Zhu G; Wang Y; Li W; Yi S; Wang K; Fan L; Tang J; Chen R
    Front Aging Neurosci; 2022; 14():877078. PubMed ID: 35572129
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease.
    Vascellari S; Palmas V; Melis M; Pisanu S; Cusano R; Uva P; Perra D; Madau V; Sarchioto M; Oppo V; Simola N; Morelli M; Santoru ML; Atzori L; Melis M; Cossu G; Manzin A
    mSystems; 2020 Sep; 5(5):. PubMed ID: 32934117
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease.
    Lin CH; Chen CC; Chiang HL; Liou JM; Chang CM; Lu TP; Chuang EY; Tai YC; Cheng C; Lin HY; Wu MS
    J Neuroinflammation; 2019 Jun; 16(1):129. PubMed ID: 31248424
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease.
    Koutzoumis DN; Vergara M; Pino J; Buddendorff J; Khoshbouei H; Mandel RJ; Torres GE
    Exp Neurol; 2020 Mar; 325():113159. PubMed ID: 31843492
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Alteration in the Cerebrospinal Fluid Lipidome in Parkinson's Disease: A Post-Mortem Pilot Study.
    Fernández-Irigoyen J; Cartas-Cejudo P; Iruarrizaga-Lejarreta M; Santamaría E
    Biomedicines; 2021 Apr; 9(5):. PubMed ID: 33946950
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease.
    Sinclair E; Trivedi DK; Sarkar D; Walton-Doyle C; Milne J; Kunath T; Rijs AM; de Bie RMA; Goodacre R; Silverdale M; Barran P
    Nat Commun; 2021 Mar; 12(1):1592. PubMed ID: 33707447
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease.
    Rosario D; Bidkhori G; Lee S; Bedarf J; Hildebrand F; Le Chatelier E; Uhlen M; Ehrlich SD; Proctor G; Wüllner U; Mardinoglu A; Shoaie S
    Cell Rep; 2021 Mar; 34(9):108807. PubMed ID: 33657381
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Gastrointestinal Dysfunction in Parkinson's Disease.
    Skjærbæk C; Knudsen K; Horsager J; Borghammer P
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33572547
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease.
    Aho VTE; Houser MC; Pereira PAB; Chang J; Rudi K; Paulin L; Hertzberg V; Auvinen P; Tansey MG; Scheperjans F
    Mol Neurodegener; 2021 Feb; 16(1):6. PubMed ID: 33557896
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders.
    Erskine D; Koss D; Korolchuk VI; Outeiro TF; Attems J; McKeith I
    Acta Neuropathol; 2021 Apr; 141(4):511-526. PubMed ID: 33515275
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
    Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
    Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics.
    Tan AH; Chong CW; Lim SY; Yap IKS; Teh CSJ; Loke MF; Song SL; Tan JY; Ang BH; Tan YQ; Kho MT; Bowman J; Mahadeva S; Yong HS; Lang AE
    Ann Neurol; 2021 Mar; 89(3):546-559. PubMed ID: 33274480
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Glycosphingolipids and neuroinflammation in Parkinson's disease.
    Belarbi K; Cuvelier E; Bonte MA; Desplanque M; Gressier B; Devos D; Chartier-Harlin MC
    Mol Neurodegener; 2020 Oct; 15(1):59. PubMed ID: 33069254
    [TBL] [Abstract][Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.